This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Höybye, C. Articles by Thorén, M. Search for Related Content PubMed PubMed Citation Articles by Höybye, C. Articles by Thorén, M.

Metabolic Profile and Body Composition in Adults with Prader-Willi Syndrome and Severe Obesity

Departments of Endocrinology and Diabetology and Radiology, Karolinska Hospital and Institute, SE-171 76 Stockholm, Sweden

Address all correspondence and requests for reprints to: Dr. Charlotte Höybye, Department of Endocrinology and Diabetology, Karolinska Hospital, SE-171 76 Stockholm, Sweden. E-mail: . charlotte.hoybye{at}ks.se

Abstract

Previous investigations of adults with the Prader-Willi syndrome (PWS) are few and have demonstrated severe obesity with increased morbidity and mortality in cardiovascular disease. It is, thus, important to identify risk factors and, if possible, start prevention. We studied the clinical, genetic, endocrinological, and metabolic findings in 19 adult PWS patients (10 men; mean age, 25 yr). The PWS karyotype was demonstrated in 13 patients. The mean body mass index was 35.6 kg/m², and total body fat was increased. Two thirds were biochemically hypogonadal. Fifty percent had severe GH deficiency (GHD). Four were hypertensive. One patient had heart failure and diabetes. Impaired glucose tolerance was seen in 4 patients, elevated homeostasis model assessment index in 9 patients, and modest dyslipidemia in 7. IGF-binding protein-1 correlated negatively with insulin levels. Four patients had osteoporosis, and 11 had osteopenia. There was no significant difference between the group with the PWS karyotype and the group without the karyotype in age, body mass index, waist/hip ratio, percent body fat, insulin values, homeostasis model assessment index, or lipid profile, except for lipoprotein(a), which was significantly higher in the group with the negative karyotype. IGF-I and lumbar spine bone mineral density were significantly lower in patients with genetic alteration, indicating a more severe GHD. The risk factors found in this study predicting cardiovascular disease are interpreted as secondary to GHD. These findings point to the importance of evaluating treatment of GHD in adults with PWS.

This article has been cited by other articles:

				R. F. A. de Lind van Wijngaarden, D. A. M. Festen, B. J. Otten, E. G. A. H. van Mil, J. Rotteveel, R. J. Odink, M. van Leeuwen, D. A. J. P. Haring, G. Bocca, E. C. A. Mieke Houdijk, et al. Bone Mineral Density and Effects of Growth Hormone Treatment in Prepubertal Children with Prader-Willi Syndrome: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3763 - 3771. [Abstract] [Full Text] [PDF]

				M. D. Seferovic, R. Ali, H. Kamei, S. Liu, J. M. Khosravi, S. Nazarian, V. K. M. Han, C. Duan, and M. B. Gupta Hypoxia and Leucine Deprivation Induce Human Insulin-Like Growth Factor Binding Protein-1 Hyperphosphorylation and Increase Its Biological Activity Endocrinology, January 1, 2009; 150(1): 220 - 231. [Abstract] [Full Text] [PDF]

				E Rossi, J Messa, and O Zuffardi Ring syndrome: still true? J. Med. Genet., November 1, 2008; 45(11): 766 - 768. [Full Text] [PDF]

				C. Chen, J. Visootsak, S. Dills, and J. M. Graham JR Prader-Willi Syndrome: An Update and Review for the Primary Pediatrician Clinical Pediatrics, September 1, 2007; 46(7): 580 - 591. [Abstract] [PDF]

				P. Marzullo, C. Marcassa, R. Campini, E. Eleuteri, A. Minocci, A. Sartorio, R. Vettor, A. Liuzzi, and G. Grugni Conditional Cardiovascular Response to Growth Hormone Therapy in Adult Patients with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1364 - 1371. [Abstract] [Full Text] [PDF]

				A. B. Goldfine, S. Crunkhorn, M. Costello, H. Gami, E. J. Landaker, M. Niinobe, K. Yoshikawa, D. Lo, A. Warren, J. Jimenez-Chillaron, et al. Necdin and E2F4 Are Modulated by Rosiglitazone Therapy in Diabetic Human Adipose and Muscle Tissue Diabetes, March 1, 2006; 55(3): 640 - 650. [Abstract] [Full Text] [PDF]

				P. Marzullo, C. Marcassa, R. Campini, E. Eleuteri, A. Minocci, L. Priano, P. Temporelli, A. Sartorio, R. Vettor, A. Liuzzi, et al. The Impact of Growth Hormone/Insulin-Like Growth Factor-I Axis and Nocturnal Breathing Disorders on Cardiovascular Features of Adult Patients with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5639 - 5646. [Abstract] [Full Text] [PDF]

				Y. H. Choe, S. Y. Song, K.-H. Paik, Y. J. Oh, S.-H. Chu, S. H. Yeo, E. K. Kwon, E. M. Kim, M. Y. Rha, and D.-K. Jin Increased Density of Ghrelin-Expressing Cells in the Gastric Fundus and Body in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5441 - 5445. [Abstract] [Full Text] [PDF]

				C. Pagano, O. Marin, A. Calcagno, P. Schiappelli, C. Pilon, G. Milan, M. Bertelli, E. Fanin, G. Andrighetto, G. Federspil, et al. Increased Serum Resistin in Adults with Prader-Willi Syndrome Is Related to Obesity and Not to Insulin Resistance J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4335 - 4340. [Abstract] [Full Text] [PDF]